{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:08:15Z","timestamp":1787170095593,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K12244"],"award-info":[{"award-number":["25K12244"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02881-4","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:10:16Z","timestamp":1757862616000},"page":"2635-2642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Takuya","family":"Oishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-9582","authenticated-orcid":false,"given":"Naoki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanao","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuma","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Noro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"2881_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2881_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00345-013-1157-5","volume":"32","author":"LA Kluth","year":"2014","unstructured":"Kluth LA, Shariat SF, Kratzik C et al (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 32:669\u2013676. https:\/\/doi.org\/10.1007\/s00345-013-1157-5","journal-title":"World J Urol"},{"key":"2881_CR3","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501\u20135511. https:\/\/doi.org\/10.1038\/onc.2013.206","journal-title":"Oncogene"},{"key":"2881_CR4","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/jco.2005.01.529","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918\u20132925. https:\/\/doi.org\/10.1200\/jco.2005.01.529","journal-title":"J Clin Oncol"},{"key":"2881_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382:2197\u20132206. https:\/\/doi.org\/10.1056\/NEJMoa2003892","journal-title":"N Engl J Med"},{"key":"2881_CR6","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383:1040\u20131049. https:\/\/doi.org\/10.1056\/NEJMoa2001342","journal-title":"N Engl J Med"},{"key":"2881_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S et al (2021) Apalutamide and overall survival in prostate cancer. Eur Urol 79:150\u2013158. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011","journal-title":"Eur Urol"},{"key":"2881_CR8","doi-asserted-by":"publisher","first-page":"e2429783","DOI":"10.1001\/jamanetworkopen.2024.29783","volume":"7","author":"DJ George","year":"2024","unstructured":"George DJ, Morgans AK, Constantinovici N et al (2024) Androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. JAMA Netw Open 7:e2429783. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.29783","journal-title":"JAMA Netw Open"},{"key":"2881_CR9","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.1200\/JCO.2022.40.16_suppl.5044","volume":"40","author":"AK Morgans","year":"2022","unstructured":"Morgans AK, Sweeney C, Wallis CJD et al (2022) Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: post-hoc analyses of ARAMIS. J Clin Oncol 40:5044\u20135044. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5044","journal-title":"J Clin Oncol"},{"key":"2881_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s10147-019-01412-2","volume":"24","author":"H Miyake","year":"2019","unstructured":"Miyake H, Matsushita Y, Watanabe H et al (2019) Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer. Int J Clin Oncol 24:842\u2013847. https:\/\/doi.org\/10.1007\/s10147-019-01412-2","journal-title":"Int J Clin Oncol"},{"key":"2881_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V et al (2015) Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41:884\u2013892. https:\/\/doi.org\/10.1016\/j.ctrv.2015.08.002","journal-title":"Cancer Treat Rev"},{"key":"2881_CR12","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/s1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S et al (2019) Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 20:1730\u20131739. https:\/\/doi.org\/10.1016\/s1470-2045(19)30688-6","journal-title":"Lancet Oncol"},{"key":"2881_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","volume":"16","author":"N Matsubara","year":"2018","unstructured":"Matsubara N, Yamada Y, Tabata KI et al (2018) Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 16:142\u2013148. https:\/\/doi.org\/10.1016\/j.clgc.2017.09.008","journal-title":"Clin Genitourin Cancer"},{"key":"2881_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pros.23141","volume":"76","author":"R Nadal","year":"2016","unstructured":"Nadal R, Tsai HL, Sinibaldi VJ et al (2016) Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. Prostate 76:512\u2013520. https:\/\/doi.org\/10.1002\/pros.23141","journal-title":"Prostate"},{"key":"2881_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/iju.13346","volume":"24","author":"N Terada","year":"2017","unstructured":"Terada N, Maughan BL, Akamatsu S et al (2017) Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int J Urol 24:441\u2013448. https:\/\/doi.org\/10.1111\/iju.13346","journal-title":"Int J Urol"},{"key":"2881_CR16","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/jco.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Saad F, Oudard S et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800\u20133806. https:\/\/doi.org\/10.1200\/jco.2012.44.6716","journal-title":"J Clin Oncol"},{"key":"2881_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.prnil.2023.10.002","volume":"11","author":"T Kawai","year":"2023","unstructured":"Kawai T, Taguchi S, Nozaki K et al (2023) Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer. Prostate Int 11:239\u2013246. https:\/\/doi.org\/10.1016\/j.prnil.2023.10.002","journal-title":"Prostate Int"},{"key":"2881_CR18","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/cncr.26437","volume":"118","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis ES, Zahurak ML, Lin J et al (2012) Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer 118:1533\u20131542. https:\/\/doi.org\/10.1002\/cncr.26437","journal-title":"Cancer"},{"key":"2881_CR19","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/pros.21377","volume":"71","author":"D Keizman","year":"2011","unstructured":"Keizman D, Huang P, Antonarakis ES et al (2011) The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate 71:1608\u20131615. https:\/\/doi.org\/10.1002\/pros.21377","journal-title":"Prostate"},{"key":"2881_CR20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/jco.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/jco.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"2881_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.juro.2008.09.049","volume":"181","author":"CN Boyd","year":"2009","unstructured":"Boyd CN (2009) Re: prostate specific antigen working group guidelines on prostate specific antigen doubling time P. M. Arlen, F. Bianco, W. L. Dahut, A. D\u2019Amico, W. D. Figg, s. J. Freedland, J. L. Gulley, P. W. Kantoff, M. W. Kattan, A. Lee, M. M. Regan and O. Sartor J Urol 2008; 179: 2181\u20132186. J Urol 181:411. https:\/\/doi.org\/10.1016\/j.juro.2008.09.049","journal-title":"J Urol"},{"key":"2881_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","volume":"18","author":"ND Shore","year":"2017","unstructured":"Shore ND (2017) Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 18:945\u2013952. https:\/\/doi.org\/10.1080\/14656566.2017.1329820","journal-title":"Expert Opin Pharmacother"},{"key":"2881_CR23","doi-asserted-by":"publisher","first-page":"728.e713","DOI":"10.1016\/j.urolonc.2021.01.030","volume":"39","author":"A Csizmarik","year":"2021","unstructured":"Csizmarik A, Hadaschik B, Kramer G et al (2021) Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer. Urol Oncol 39:728.e713-728.e724. https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.030","journal-title":"Urol Oncol"},{"key":"2881_CR24","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.drup.2021.100761","volume":"56","author":"SAJ Buck","year":"2021","unstructured":"Buck SAJ, Koolen SLW, Mathijssen RHJ et al (2021) Cross-resistance and drug sequence in prostate cancer. Drug Resist Updat 56:100761. https:\/\/doi.org\/10.1016\/j.drup.2021.100761","journal-title":"Drug Resist Updat"},{"key":"2881_CR25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1158\/1535-7163.Mct-20-0015","volume":"19","author":"J Zhao","year":"2020","unstructured":"Zhao J, Ning S, Lou W et al (2020) Cross-resistance among next-generation antiandrogen drugs through the AKR1C3\/AR-V7 axis in advanced prostate cancer. Mol Cancer Ther 19:1708\u20131718. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0015","journal-title":"Mol Cancer Ther"},{"key":"2881_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.euo.2019.09.005","volume":"4","author":"MCP Kuppen","year":"2021","unstructured":"Kuppen MCP, Westgeest HM, van den Eertwegh AJM et al (2021) Real-world outcomes of sequential androgen-receptor targeting therapies with or without interposed life-prolonging drugs in metastatic castration-resistant prostate cancer: results from the Dutch castration-resistant prostate cancer registry. Eur Urol Oncol 4:618\u2013627. https:\/\/doi.org\/10.1016\/j.euo.2019.09.005","journal-title":"Eur Urol Oncol"},{"key":"2881_CR27","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/annonc\/mdx283","volume":"28","author":"DE Rathkopf","year":"2017","unstructured":"Rathkopf DE, Smith MR, Ryan CJ et al (2017) Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol 28:2264\u20132271. https:\/\/doi.org\/10.1093\/annonc\/mdx283","journal-title":"Ann Oncol"},{"key":"2881_CR28","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1007\/s10147-024-02637-6","volume":"29","author":"Y Yamamoto","year":"2024","unstructured":"Yamamoto Y, Fujimoto S, Hashimoto M et al (2024) Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor. Int J Clin Oncol 29:1946\u20131958. https:\/\/doi.org\/10.1007\/s10147-024-02637-6","journal-title":"Int J Clin Oncol"},{"key":"2881_CR29","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815","journal-title":"N Engl J Med"},{"key":"2881_CR30","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1038\/s41467-023-37647-x","volume":"14","author":"AC de Jong","year":"2023","unstructured":"de Jong AC, Danyi A, van Riet J et al (2023) Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. Nat Commun 14:1968. https:\/\/doi.org\/10.1038\/s41467-023-37647-x","journal-title":"Nat Commun"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02881-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02881-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02881-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:03:50Z","timestamp":1764180230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02881-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2881"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02881-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6935071\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,14]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Kaneka Corporation, and Nipro Corporation. None of the other authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study adhered to the principles of the Declaration of Helsinki and was approved by the ethics committees of the Hirosaki University Graduate School of Medicine (authorization number: 2019\u2013099-1 and 2021\u2013158-2) and all participating hospitals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for written informed consent was waived because of the use of a public disclosure of study information (opt-out approach).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}